{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:52:57Z","timestamp":1781650377594,"version":"3.54.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Chronic allograft dysfunction (CAD) remains a leading cause of graft loss after kidney transplantation. Dapagliflozin (DAPA) has shown renal and cardiometabolic benefits in nontransplanted patients with chronic kidney disease. However, data on recipients with CAD are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      Adult kidney transplant recipients (n\u2005=\u2005208), with estimated glomerular filtration rate (eGFR) 25\u201345\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      or 45\u201360\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      with \u226510% annual decline, were randomized to receive DAPA 10\u2009mg\/d or placebo for 12 mo. The outcomes were differences in eGFR, in eGFR slopes, proteinuria, blood pressure, body mass index (BMI), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      There was no difference in eGFR between groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.611). However, at month 12, eGFR was higher in the PLACEBO group (n\u2005=\u2005102; 39.4\u2005\u00b1\u20050.9 vs 36.5\u2005\u00b1\u20050.9\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.029). In the DAPA group (n\u2005=\u2005106), the least square means (LSM) of eGFR slopes was \u20130.86\u2005\u00b1\u20050.65\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      at the third month while remaining at \u20130.75\u2005\u00b1\u20050.65\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      at 12 mo. The PLACEBO group presented an LSM slope of \u20130.34\u2005\u00b1\u2005067\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      at 3 mo and +0.51\u2005\u00b1\u200566\u2009mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      at 12 mo. In a per-protocol analysis, patients in the DAPA group (n\u2005=\u200586) under angiotensin-converting enzyme inhibitor\/ angiotensin receptor blockers (n\u2005=\u200523) did not present an eGFR dip, but those not under angiotensin-converting enzyme inhibitor\/ angiotensin receptor blockers (n\u2005=\u200563) did. DAPA reduced proteinuria from 267 to 84\u2009mg\/g (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001), body weight by 2\u2009kg (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02), BMI by 0.7\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.023), systolic blood pressure by 7 mm\u2009Hg (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.014), diastolic blood pressure from baseline to 9 mo (80.5\u2005\u00b1\u20051.2 vs 76.8\u2005\u00b1\u20051.2 mm\u2009Hg,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.021), and glycated hemoglobin in patients with diabetes by 0.5% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.04). The incidence of serious adverse events did not differ between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>In kidney transplant recipients with CAD, DAPA did not improve eGFR compared with placebo, but presented reductions in proteinuria, blood pressure, BMI, and glycated hemoglobin, with acceptable safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005741","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:02:33Z","timestamp":1778266953000},"page":"e1527-e1538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial"],"prefix":"10.1097","volume":"110","author":[{"given":"Elias","family":"David-Neto","sequence":"first","affiliation":[{"name":"Kidney Transplantation Service of Hospital das Cl\u00ednicas - Faculdade de Medicina da Universidade de S\u00e3o Paulo (USP), S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Elias Ribeiro","family":"David","sequence":"additional","affiliation":[{"name":"Kidney Transplantation Service of Hospital das Cl\u00ednicas - Faculdade de Medicina da Universidade de S\u00e3o Paulo (USP), S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Alves","sequence":"additional","affiliation":[{"name":"Hospital do Rim \u2013 Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Otto","family":"Reusing","sequence":"additional","affiliation":[{"name":"Kidney Transplantation Service of Hospital das Cl\u00ednicas - Faculdade de Medicina da Universidade de S\u00e3o Paulo (USP), S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lembe","sequence":"additional","affiliation":[{"name":"Hospital do Rim \u2013 Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Zocoler","family":"Galante","sequence":"additional","affiliation":[{"name":"Kidney Transplantation Service of Hospital das Cl\u00ednicas - Faculdade de Medicina da Universidade de S\u00e3o Paulo (USP), S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayra","family":"Silva","sequence":"additional","affiliation":[{"name":"Hospital do Rim \u2013 Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Soares","family":"de Souza","sequence":"additional","affiliation":[{"name":"Kidney Transplantation Service of Hospital das Cl\u00ednicas - Faculdade de Medicina da Universidade de S\u00e3o Paulo (USP), S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Hospital do Rim \u2013 Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio Tedesco","family":"Silva","sequence":"additional","affiliation":[{"name":"Hospital do Rim \u2013 Funda\u00e7\u00e3o Oswaldo Ramos, S\u00e3o Paulo, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"R1-20260616","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/ki.1996.265","article-title":"The hyperfiltration theory: a paradigm shift in nephrology.","volume":"49","author":"Brenner","year":"1996","journal-title":"Kidney Int"},{"key":"R2-20260616","doi-asserted-by":"crossref","first-page":"F1041","DOI":"10.1152\/ajprenal.00005.2024","article-title":"SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake.","volume":"326","author":"Albalawy","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"R3-20260616","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFbeta1\/Smad signaling.","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R4-20260616","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20260616","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"R6-20260616","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20260616","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"R8-20260616","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial.","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R9-20260616","first-page":"47","article-title":"Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis.","volume":"8","author":"Chewcharat","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"R10-20260616","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation: a systematic review and meta-analysis.","volume":"110","author":"Lee","year":"2026","journal-title":"Transplantation"},{"key":"R11-20260616","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ekir.2024.11.033","article-title":"Sodium-glucose cotransporter-2 inhibitor in diabetic and nondiabetic renal transplant recipients.","volume":"10","author":"Maigret","year":"2025","journal-title":"Kidney Int Rep"},{"key":"R12-20260616","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients.","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"R13-20260616","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients.","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat Commun"},{"key":"R14-20260616","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"R15-20260616","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1097\/TXD.0000000000001228","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients.","volume":"7","author":"Hisadome","year":"2021","journal-title":"Transplant Direct"},{"key":"R16-20260616","doi-asserted-by":"crossref","first-page":"e14718","DOI":"10.1111\/ctr.14718","article-title":"Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.","volume":"36","author":"Lemke","year":"2022","journal-title":"Clin Transplant"},{"key":"R17-20260616","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12882-022-02793-9","article-title":"Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: five Japanese cases.","volume":"23","author":"Miyazaki","year":"2022","journal-title":"BMC Nephrol"},{"key":"R18-20260616","doi-asserted-by":"crossref","first-page":"e00185","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients.","volume":"4","author":"Song","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"R19-20260616","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/TP.0b013e318288caa6","article-title":"MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients.","volume":"95","author":"Masson","year":"2013","journal-title":"Transplantation"},{"key":"R20-20260616","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","article-title":"Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition.","volume":"146","author":"Lytvyn","year":"2022","journal-title":"Circulation"},{"key":"R21-20260616","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R22-20260616","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy.","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R23-20260616","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe2215286","article-title":"Chronic kidney disease\u2014another step forward.","volume":"388","author":"August","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20260616","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R25-20260616","doi-asserted-by":"crossref","first-page":"112515","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na(+)](c)\/ROS-pathway in human endothelial cells.","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R26-20260616","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"R27-20260616","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"R28-20260616","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMc1611290","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wakisaka","year":"2016","journal-title":"N Engl J Med"},{"key":"R29-20260616","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency.","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R30-20260616","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:49Z","timestamp":1781647249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005741","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}